Drug Profile
Cavrotolimod - Exicure
Alternative Names: AST 008Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Exicure
- Class Antineoplastics; Immunotherapies; Oligonucleotides
- Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Haematological malignancies; Merkel cell carcinoma; Solid tumours; Squamous cell cancer
Most Recent Events
- 05 Feb 2024 Cavrotolimod licensed to Bluejay Therapeutics
- 30 Mar 2022 Exicure terminates a phase Ib/II trial in Merkel cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (Intratumoural) (NCT03684785)
- 30 Mar 2022 Exicure terminates a phase Ib/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (Intratumoural) (NCT03684785)